Vorinostat and Velcade combination active in refractory myeloma patients

Data from the global multi-centre Phase IIb VANTAGE 095 trial have demonstrated that the histone deacetylase inhibitor, vorinostat, in combination with Velcade is effective in myeloma patients who are considered to be refractory to conventional anti-myeloma treatment. Published recently in Clinical Lymphoma Myeloma & Leukemia, the results showed an objective response rate of 11.3%, median…

Details